Correlation between plasma concentrations of homocysteine and diabetic polyneuropathy evaluated with the Semmes-Weinstein monofilament test in patients with type 2 diabetes mellitus;Correlación entre las concentraciones plasmáticas de homocisteína y la polineuropatía diabética evaluada con la prueba del monofilamento de Semmes-Weinstein en pacientes con diabetes tipo 2

Medicina Clinica

Volumn 141, Issue 9, 2013, Pages 382-386

  Molina, Mercedes ^a   Gonzalez, Ricardo ^b   Folgado, José ^a   Real, José T ^a,c,d   Martínez Hervás, Sergio ^a,c   Priego, Antonia ^a   Lorente, Rosario ^a   Chaves, F Javier ^c   Ascaso, Juan F ^a,c,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Centro de Salud Nazaret   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Diabetic polineuropathy; Homocysteine; Monofilament

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN A1C; HOMOCYSTEINE;

ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEUROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETIC POLINEUROPATHY; HOMOCISTEÍNA; HOMOCYSTEINE; MONOFILAMENT; MONOFILAMENTO; POLINEUROPATÍA DIABÉTICA;

AGE FACTORS; AGED; ALCOHOL DRINKING; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; FOLIC ACID; HEMOGLOBIN A, GLYCOSYLATED; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPESTHESIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; OVERWEIGHT; PHYSICAL EXAMINATION; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; VITAMIN B 12;

EID: 84886445391     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2012.09.042     Document Type: Article

References (24)

1. R.M. Pascuzzi Peripheral neuropathy Med Clin North Am 93 2009 317 342
2. L.A. Lavery, D.G. Armstrong, S.A. Vela, T.L. Quebedeaux, and J.G. Fleischli Practical criteria for screening patients at high risk for diabetic foot ulceration Arch Intern Med 158 1998 157 162
3. The Diabetes Control and Complications Trial Research Group Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT) Diabetes 37 1988 476 481
4. D. Mahmood, B.K. Singh, and M. Akhtar Diabetic neuropathy: Therapies on the horizon J Pharm Pharmacol 61 2009 1137 1145
5. S.G. Bruce, and T.K. Young Prevalence and risk factors for neuropathy in a Canadian community Diabetes Care 31 2008 1837 1841
6. A. Ambrosch, J. Dierkes, R. Lobmann, W. Kühne, W. König, and C. Luley Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus Diabet Med 18 2001 185 192
7. D.A. De Luis, N. Fernandez, M.L. Arranz, R. Aller, O. Izaola, and E. Romero Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2 J Diabetes Complications 19 2005 42 46
8. J.A. Cohen, B.W. Jeffers, S. Stabler, R.W. Schrier, and R. Estascio Increasing homocysteine levels and diabetic autonomic neuropathy Auton Neurosci 87 2001 268 273
9. O. Vaccaro, A.F. Perna, F.P. Mancini, C. Iovine, V. Cuomo, and M. Sacco Plasma homocysteine and microvascular complications in type 1 diabetes Nutr Metab Cardiovasc Dis 10 2000 297 304
10. L. Papatheodorou, and N. Weiss Vascular oxidant stress and inflammation in hyperhomocysteinemia Antioxid Redox Signal 9 2007 1941 1958
11. C. Aguirre Errasti, M.V. Egurbide Arberas, and A. Martínez Berriotxoa Homocisteína en la clínica humana Med Clin (Barc) 133 2009 472 478
12. E. Schlussel Homocysteine-induced oxidative damage: Mechanisms and possible roles in neurodegenerative and atherogenic processes Z Naturforsch 50 1995 699 707
13. Y. Feng, F.J. Schlösser, and B.E. Sumpio The Semmes Weinstein monofilament examination as a screening tool for diabetic peripheral neuropathy J Vasc Surg 50 2009 675 682
14. J.J. De Sonnaville, M. Bouma, L.P. Colly, W. Devillé, and D. Wijkel Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study Diabetologia 40 1997 1334 1340
15. M.I. Burgos, M. Fenollar, F. Avilés, and M.S. Parra Patrón diferencial de homocisteína en pacientes con enfermedad arterial periférica Med Clin (Barc) 134 2010 467 469
16. C.J. Boushey A quantitative assessment of plasma homocysteine as a risk factor for vascular disease JAMA 274 1995 1049 1057
17. M.A. Allison, M.H. Criqui, R.L. McClelland, J.M. Scott, M.M. McDermott, and K. Liu The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA) J Am Coll Cardiol 48 2006 1190 1197
18. M. Vega de Cerriga, L. Estallo, M. Esteban Solan, E. Bravo, M. Izaguirre, and A. Barba Valor pronóstico de marcadores inflamatorios y perfil lipídico en pacientes con claudicación intermitente. Estudio piloto Med Clin (Barc) 136 2011 244 247
19. L. Jianbo, C. Yuche, S. Ming, T. Jingrong, D. Qing, and Z. Yu Association of homocysteine with peripheral neuropathy in Chinese patients with type 2 diabetes Diabetes Res Clin Pract 93 2011 38 42
20. R. González, T. Pedro, J.T. Real, S. Martínez- Hervás, M.R. Abellán, and R. Lorente Plasma homocysteine levels are associated with ulceration of the foot in patients with type 2 diabetes mellitus Diabetes Metab Res Rev 26 2010 115 120
21. D.J. Wile, and C. Toth Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy Diabetes Care 33 2010 156 161
22. M.R. Taskinen, D.R. Sullivan, C. Ehnholm, M. Whiting, D. Zannino, R.J. Simes FIELD study investigators Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate Arterioscler Thromb Vasc Biol 29 2009 950 955
23. M. Lever, P.M. George, S. Slow, J.L. Elmslie, R.S. Scott, and A.M. Richards Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine Cardiovasc Drugs Ther 23 2009 395 401
24. K.T. Williams, and K.L. Schalinske Homocysteine metabolism and its relation to health and disease Biofactors 36 2010 19 24